May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Control of Ocular Allergy Symptoms by Epinastine HCl 0.05% in a Conjunctival Antigen Challenge Evaluation
Author Affiliations & Notes
  • M.H. Friedlaender
    Ophthalmology, Scripps Clinic, La Jolla, CA
  • L. Sharf
    Ophthalmology, Scripps Clinic, La Jolla, CA
  • D. Breshears
    Ophthalmology, Scripps Clinic, La Jolla, CA
  • Footnotes
    Commercial Relationships  M.H. Friedlaender, Allergan F; L. Sharf, None; D. Breshears, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4841. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.H. Friedlaender, L. Sharf, D. Breshears; Control of Ocular Allergy Symptoms by Epinastine HCl 0.05% in a Conjunctival Antigen Challenge Evaluation . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4841.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Efficacy evaluation of epinastine HCl 0.05%, a new topical ophthalmic antihistamine with mast cell–stabilizing and anti–inflammatory properties, using the conjunctival antigen challenge (CAC) model. Methods: This was a single–center, randomized, investigator–masked, vehicle–controlled study. Participants (N=24) were female, 18–75 years old, and had a history of allergic conjunctivitis. On day 0, the amount of antigen that elicited itching and hyperemia scores of 2 or greater (on a scale of 0–4) was established as the threshold dose. On day 7, each patient was assigned to receive 1 drop of epinastine HCl 0.05% ophthalmic solution in one eye and vehicle in the other eye in randomized fashion, 5 minutes prior to CAC (onset of efficacy assessment). On day 14, study drug was instilled 12 hours prior to CAC (duration of efficacy assessment). Results: Patients’ mean age was 43.0 years (range 23–60). In the onset of efficacy assessment, eyes treated with epinastine 5 minutes before antigen challenge showed a mean itching score of 1.14 at 5 minutes post–challenge, compared with 2.07 for eyes treated with vehicle (P = .008). The onset mean hyperemia scores at 5 minutes post–challenge were 0.86 for epinastine–treated eyes and 1.93 for vehicle–treated eyes (P = .026). In the duration of efficacy assessment, eyes treated with epinastine 12 hours before antigen challenge had a mean itching score of 1.00 at 5 minutes post–challenge, compared with 2.25 for eyes treated with vehicle (P = .011). Conclusions: Treatment with epinastine HCl 0.05% ophthalmic solution significantly reduced ocular allergy symptoms compared with vehicle in this conjunctival antigen challenge trial. Epinastine relieved ocular allergy symptoms rapidly and showed a long duration of efficacy.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • conjunctivitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×